Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Operating Leases (2019 - 2025)

Historic Operating Leases for UroGen Pharma (URGN) over the last 7 years, with Q3 2025 value amounting to $6.2 million.

  • UroGen Pharma's Operating Leases rose 50183.22% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 50183.22%. This contributed to the annual value of $1.7 million for FY2024, which is 9585.31% up from last year.
  • As of Q3 2025, UroGen Pharma's Operating Leases stood at $6.2 million, which was up 50183.22% from $3.4 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Operating Leases high stood at $6.2 million for Q3 2025, and its period low was $398000.0 during Q4 2021.
  • For the 5-year period, UroGen Pharma's Operating Leases averaged around $1.9 million, with its median value being $1.7 million (2024).
  • As far as peak fluctuations go, UroGen Pharma's Operating Leases tumbled by 7341.35% in 2021, and later surged by 53492.46% in 2022.
  • Quarter analysis of 5 years shows UroGen Pharma's Operating Leases stood at $398000.0 in 2021, then surged by 534.92% to $2.5 million in 2022, then plummeted by 66.6% to $844000.0 in 2023, then soared by 95.85% to $1.7 million in 2024, then skyrocketed by 277.56% to $6.2 million in 2025.
  • Its Operating Leases was $6.2 million in Q3 2025, compared to $3.4 million in Q2 2025 and $2.8 million in Q1 2025.